Incannex Healthcare Inc.NASDAQ: IXHL

Incannex Healthcare kicks off Phase 2 rheumatoid arthritis trial

· Issued by Incannex Healthcare Inc.

--News Direct--

Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has begun a Phase 2 clinical trial, testing the safety and efficacy of its IHL-657A drug candidate in patients with rheumatoid arthritis. Research firm Avance Clinical will manage the trial across up to 10 sites in Australia and New Zealand, overseeing responses from 120 participants as they evaluate how IHL-657A treats patient pain and function over 24 weeks.

Watch the video on YouTube

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

[email protected]

View source version on newsdirect.com: https://newsdirect.com/news/incannex-healthcare-kicks-off-phase-2-rheumatoid-arthritis-trial-805244015

Incannex Healthcare Inc. on 6ix

Earlier from Incannex Healthcare

Later from Incannex Healthcare

All Incannex Healthcare news releases